Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Atalanta Sosnoff Capital LLC

Atalanta Sosnoff Capital LLC decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 62.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 45,202 shares of the pharmaceutical company’s stock after selling 74,236 shares during the quarter. Atalanta Sosnoff Capital LLC’s holdings in Vertex Pharmaceuticals were worth $18,203,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of VRTX. Brown Lisle Cummings Inc. acquired a new stake in Vertex Pharmaceuticals during the fourth quarter worth approximately $30,000. Sugar Maple Asset Management LLC purchased a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth $35,000. Golden State Wealth Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $37,000. Truvestments Capital LLC grew its position in shares of Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock valued at $40,000 after purchasing an additional 23 shares during the period. Finally, ORG Partners LLC increased its stake in Vertex Pharmaceuticals by 108.2% in the fourth quarter. ORG Partners LLC now owns 102 shares of the pharmaceutical company’s stock valued at $41,000 after purchasing an additional 53 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $501.15 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average of $492.00 and a 200-day moving average of $467.15. The stock has a market cap of $128.84 billion, a P/E ratio of -227.80, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the sale, the executive vice president now owns 26,512 shares in the company, valued at $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Ourania Tatsis sold 244 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the transaction, the executive vice president now owns 67,695 shares in the company, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,315 shares of company stock valued at $2,121,012 over the last three months. 0.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of research analyst reports. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and increased their price target for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $535.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, April 22nd. Morgan Stanley lifted their target price on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. Finally, HC Wainwright restated a “buy” rating and set a $550.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Ten investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $514.91.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.